Plasmid DNA Vaccine Candidate's Phase 1 Study Targets Rare But Aggressive Form of Skin Cancer

Colorado-based PharmaJet® announced today that its partner Immunomic Therapeutics would start an early-stage clinical study of their plasmid DNA vaccine ITI-3000 in patients with Merkel cell carcinoma (MCC), a rare but rare aggressive form of skin cancer.

The study will exclusively use the Stratis® Needle-free injection System to deliver the vaccine.

The PharmaJet Needle-free System was chosen due to its ability to precisely deliver the vaccine to the intramuscular tissue layer.

Chris Cappello, President and CEO of PharmaJet commented in a press statement issued on March 15, 2022, "We are pleased to be collaborating with our partner in this important therapeutic DNA vaccine clinical trial for this aggressive skin cancer."

"Our PharmaJet Needle-free Systems have been successfully used for the prevention or treatment of HPV-related lesions, Lymphoma, and solid tumors, among other oncology indications."

Previously, Immunomic confirmed the trial is a Phase 1, open-label, First in Humans study to evaluate the safety, tolerability, and immunogenicity of 4 mg of ITI-3000 in patients with MCC patients who have undergone surgery.

Dr. William Hearl, CEO of Immunomic Therapeutics, stated in a press release issued on February 7, 2022, "Based on the strength of our UNITE platform and strong pre-clinical data generated, to date, we believe ITI-3000 has the potential to address the urgent unmet medical need for therapies to treat this aggressive form of skin cancer."

For more information about PharmaJet, visit www.pharmajet.com.

Note: This news post combined two press releases edited for clarity.